Annual Accounts Payable
$1.78 M
-$741.00 K-29.33%
01 June 2022
Summary:
Pluristem Therapeutics annual accounts payable is currently $1.78 million, with the most recent change of -$741.00 thousand (-29.33%) on 01 June 2022. During the last 3 years, it has fallen by -$741.00 thousand (-29.33%).PSTI Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$1.33 M
-$456.00 K-25.55%
01 September 2022
Summary:
Pluristem Therapeutics quarterly accounts payable is currently $1.33 million, with the most recent change of -$456.00 thousand (-25.55%) on 01 September 2022.PSTI Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTI Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | -29.3% | -42.3% |
| 5 y5 years | -21.7% | -54.0% |
PSTI Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | -48.5% | -61.6% |
Pluristem Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $1.33 M(-25.5%) |
| June 2022 | $1.78 M(-29.3%) | $1.78 M(-25.4%) |
| Mar 2022 | - | $2.39 M(-8.1%) |
| Dec 2021 | - | $2.61 M(+13.2%) |
| Sept 2021 | - | $2.30 M(-8.8%) |
| June 2021 | $2.53 M(+28.4%) | $2.53 M(+19.7%) |
| Mar 2021 | - | $2.11 M(-26.1%) |
| Dec 2020 | - | $2.85 M(+59.0%) |
| Sept 2020 | - | $1.79 M(-8.8%) |
| June 2020 | $1.97 M(-13.7%) | $1.97 M(+8.7%) |
| Mar 2020 | - | $1.81 M(-2.5%) |
| Dec 2019 | - | $1.86 M(-35.7%) |
| Sept 2019 | - | $2.89 M(+26.7%) |
| June 2019 | $2.28 M(-30.1%) | $2.28 M(-21.1%) |
| Mar 2019 | - | $2.89 M(+39.5%) |
| Dec 2018 | - | $2.07 M(-2.8%) |
| Sept 2018 | - | $2.13 M(-34.6%) |
| June 2018 | $3.26 M(+65.9%) | $3.26 M(+69.5%) |
| Mar 2018 | - | $1.92 M(+6.4%) |
| Dec 2017 | - | $1.81 M(+16.4%) |
| Sept 2017 | - | $1.55 M(-21.0%) |
| June 2017 | $1.97 M(-27.3%) | $1.97 M(+17.1%) |
| Mar 2017 | - | $1.68 M(-39.5%) |
| Dec 2016 | - | $2.77 M(+21.3%) |
| Sept 2016 | - | $2.29 M(-15.4%) |
| June 2016 | $2.71 M(-17.2%) | $2.71 M(+37.4%) |
| Mar 2016 | - | $1.97 M(+7.2%) |
| Dec 2015 | - | $1.83 M(+22.7%) |
| Sept 2015 | - | $1.50 M(-54.3%) |
| June 2015 | $3.27 M(-5.7%) | $3.27 M(+36.5%) |
| Mar 2015 | - | $2.40 M(-5.0%) |
| Dec 2014 | - | $2.52 M(+4.2%) |
| Sept 2014 | - | $2.42 M(-30.1%) |
| June 2014 | $3.46 M(+22.1%) | $3.46 M(+28.5%) |
| Mar 2014 | - | $2.70 M(-0.6%) |
| Dec 2013 | - | $2.71 M(-5.9%) |
| Sept 2013 | - | $2.88 M(+1.5%) |
| June 2013 | $2.84 M(+107.4%) | $2.84 M(+10.1%) |
| Mar 2013 | - | $2.58 M(-24.1%) |
| Dec 2012 | - | $3.40 M(+40.1%) |
| Sept 2012 | - | $2.42 M(+77.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2012 | $1.37 M(+16.2%) | $1.37 M(-37.6%) |
| Mar 2012 | - | $2.19 M(+15.6%) |
| Dec 2011 | - | $1.90 M(+8.6%) |
| Sept 2011 | - | $1.75 M(+48.3%) |
| June 2011 | $1.18 M(+48.8%) | $1.18 M(-34.5%) |
| Mar 2011 | - | $1.80 M(+29.0%) |
| Dec 2010 | - | $1.39 M(+29.9%) |
| Sept 2010 | - | $1.07 M(+35.7%) |
| June 2010 | $791.00 K(+4.2%) | $791.00 K(-25.6%) |
| Mar 2010 | - | $1.06 M(+9.1%) |
| Dec 2009 | - | $974.00 K(+20.0%) |
| Sept 2009 | - | $812.00 K(+7.0%) |
| June 2009 | $759.00 K(-17.3%) | $759.00 K(+22.4%) |
| Mar 2009 | - | $620.00 K(-19.3%) |
| Dec 2008 | - | $768.00 K(+90.6%) |
| Sept 2008 | - | $403.00 K(-56.1%) |
| June 2008 | $918.00 K(+59.4%) | $918.00 K(+49.0%) |
| Mar 2008 | - | $616.00 K(-7.4%) |
| Dec 2007 | - | $665.00 K(-6.2%) |
| Sept 2007 | - | $709.00 K(+23.1%) |
| June 2007 | $575.90 K(+63.7%) | $575.90 K(-77.1%) |
| Mar 2007 | - | $2.51 M(+818.4%) |
| Dec 2006 | - | $273.30 K(+64.4%) |
| Sept 2006 | - | $166.20 K(-52.8%) |
| June 2006 | $351.80 K(+90.1%) | $351.80 K(+87.4%) |
| Mar 2006 | - | $187.70 K(+33.1%) |
| Dec 2005 | - | $141.00 K(-28.7%) |
| Sept 2005 | - | $197.70 K(+6.8%) |
| June 2005 | $185.10 K(+64.0%) | $185.10 K(+301.5%) |
| Mar 2005 | - | $46.10 K(-58.3%) |
| Dec 2004 | - | $110.60 K(+81.6%) |
| Sept 2004 | - | $60.90 K(-46.1%) |
| June 2004 | $112.90 K(-14.9%) | $112.90 K(-69.6%) |
| Mar 2004 | - | $371.10 K(+306.5%) |
| Dec 2003 | - | $91.30 K(-4.7%) |
| Sept 2003 | - | $95.80 K(-27.8%) |
| June 2003 | $132.60 K(+1187.4%) | $132.60 K(+416.0%) |
| Mar 2003 | - | $25.70 K(+37.4%) |
| Dec 2002 | - | $18.70 K(+52.0%) |
| Sept 2002 | - | $12.30 K(+19.4%) |
| June 2002 | $10.30 K | $10.30 K |
FAQ
- What is Pluristem Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Pluristem Therapeutics?
- What is Pluristem Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Pluristem Therapeutics?
What is Pluristem Therapeutics annual accounts payable?
The current annual accounts payable of PSTI is $1.78 M
What is the all time high annual accounts payable for Pluristem Therapeutics?
Pluristem Therapeutics all-time high annual accounts payable is $3.46 M
What is Pluristem Therapeutics quarterly accounts payable?
The current quarterly accounts payable of PSTI is $1.33 M
What is the all time high quarterly accounts payable for Pluristem Therapeutics?
Pluristem Therapeutics all-time high quarterly accounts payable is $3.46 M